Azactam™

Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

INDICATIONS AS AT 23 MAY 1991: 1. Azactam is indicated for use as a single agent in the treatment of infections known or strongly suspected to be due to susceptible gram negative aerobes, such as urinary tract infection, gonorrhoea, etc. 2. In combination with other suitable antibiotics to treat serious infections due to problem organisms known or likely to be susceptible to aztreonam. Some patients with serious Pseudomonas infections may benefit from concurrent use of Azactam and an aminoglycoside because of synergistic action. However, this enhanced activity is not predictable. If such concurrent therapy is considered in patients with serious infections, susceptibility tests should be performed in vitro to determine the activity of the drugs in combination. Because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics, renal function should be monitored according to the aminoglycoside manufacturer's prescribing information, especially if high dosages of the aminoglycoside are to be used or if therapy is prolonged. 3. Meningitis caused by Haemophilus influenzae or Neisseria meningitidis. Azactam should not be used alone, but only in combination with other suitable antibiotics, in cases where meningitis is known or presumed to be due to the above organisms. Appropriate therapy should be instituted when results of sensitivity tests are known. Before instituting treatment with Azactam, appropriate specimens should be obtained for isolation of the causative organism(s) and for determination of susceptibility to aztreonam. Treatment with Azactam should normally be initiated on the basis of susceptibility tests, but it may be initiated in the above situations before the results of identification and sensitivity testing of the causative organism become available.

Source: ARTG

• Shelf lifetime is 4 Years
• Store below 30 degrees Celsius

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Injection, powder for
• Intramuscular
• White to off-white, free flowing powder

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 10 x 1 g

Source: ARTG

This medicine is not listed on the Pharmaceutical Benefits Scheme (PBS). Talk to your pharmacist about how much it will cost.

Source: PBS

For the active ingredient: Aztreonam

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).

You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)

Source: ARTG

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).